Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 813-819

  Barry, Elly ^a   DeAngelo, Daniel J ^b   Neuberg, Donna ^b   Stevenson, Kristen ^b   Loh, Mignon L ^b   Asselin, Barbara L ^b   Barr, Ronald D ^b   Clavell, Luis A ^b   Hurwitz, Craig A ^b   Moghrabi, Albert ^b   Samson, Yvan ^b   Schorin, Marshall ^b   Cohen, Harvey J ^b   Sallan, Stephen E ^b   Silverman, Lewis B ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PREDNISONE; RAZOXANE; VINCRISTINE; ONCOPROTEIN; TEL AML1 FUSION PROTEIN; TEL-AML1 FUSION PROTEIN; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; T LYMPHOCYTE; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES; ACUTE LYMPHOCYTIC LEUKEMIA; AGE; COMPARATIVE STUDY; GENETICS; INFANT; MORTALITY; PHILADELPHIA 1 CHROMOSOME; PRESCHOOL CHILD;

ADOLESCENT; AGE FACTORS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; ONCOGENE PROTEINS, FUSION; PHILADELPHIA CHROMOSOME;

EID: 33947498417     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.6397     Document Type: Article

References (26)

1. Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18-24, 1996
2. Moricke A, Zimmermann M, Reiter A, et al: Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: Data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 217:310-320, 2005
3. Miller DR, Leikin S, Albo V, et al: Use of prognostic factors in improving the design and efficiency of clinical trials in childhood leukemia: Children's Cancer Study Group Report. Cancer Treat Rep 64:381-392, 1980
4. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218, 2001
5. Tzortzatou-Stathopoulou F, Moschovi MA, Papadopoulou AL, et al: Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors? Eur J Haematol 75:361-369, 2005
6. Hutchinson RJ, Gaynon PS, Sather H, et al: Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: Long-term follow-up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 21:1790-1797, 2003
7. Pui CH, Sandlund JT, Pei D, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104:2690-2696, 2004
8. Schrappe M, Reiter A, Ludwig WD, et al: Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90 - German-Austrian-Swiss ALL-BFM Study Group. Blood 95:3310-3322, 2000
9. Nachman J, Sather HN, Buckley JD, et al: Young adults 16-21 years of age at diagnosis entered on Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols: Results of treatment. Cancer 71:3377-3385, 1993
10. Santana VM, Dodge RK, Crist WM, et al: Presenting features and treatment outcome of adolescents with acute lymphoblastic leukemia. Leukemia 4:87-90, 1990
11. Rivera GK, Pui CH, Santana VM, et al: Progress in the treatment of adolescents with acute lymphoblastic leukemia. Cancer 71:3400-3405, 1993
12. Irken G, Oren H, Gulen H, et al: Treatment outcome of adolescents with acute lymphoblastic leukemia. Ann Hematol 81:641-645, 2002
13. Boissel N, Auclerc MF, Lheritier V, et al: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774-780, 2003
14. Ramanujachar R, Richards S, Hann I, et al: Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 48:254-261, 2007
15. Stock W, Sather H, Dodge RK, et al: Outcome of adolescents and young adults with ALL: A comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens. Blood 96:467a, 2000
16. de Bont JM, Holt B, Dekker AW, et al: Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18:2032-2035, 2004
17. Loh ML, Goldwasser MA, Silverman LB, et al: Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 107:4508-4513, 2006
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
20. Testi A, Valsecch MG, Conter V, et al: Differences in outcome of adolescents with acute lymphoblastic leukemia enrolled in paediatric (AIEOP) and adult (GIMEMA) protocols. Blood 104:1954a, 2004
21. Deangelo DJ: The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2005:123-130, 2005
22. Goldberg JM, Silverman LB, Levy DE, et al: Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21:3616-3622, 2003
23. Gaynon PS, Qu RP, Chappell RJ, et al: Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse - The Children's Cancer Group Experience. Cancer 82:1387-1395, 1998
24. Buhrer C, Hartmann R, Fengler R, et al: Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia. Med Pediatr Oncol 21:470-476, 1993
25. Sutton L, Chastang C, Ribaud P, et al: Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88:358-365, 1996
26. Cahn JY, Labopin M, Schattenberg A, et al: Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years: Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 11:416-419, 1997